Lactoferrin for COVID-19 prevention, treatment, and recovery

Basit Öğe Kaydı
dc.authoridSaritas, Sumeyye/0009-0003-4485-3208
dc.authoridSAHUTOGLU, Arif Sercan/0000-0003-1183-3553
dc.authoridBolat, Ecem/0009-0001-7086-3317
dc.authoridKARAV, SERCAN/0000-0003-4056-1673
dc.authoridEker, Furkan/0009-0002-5260-6111
dc.authoridKaplan, Merve/0000-0002-3322-0988
dc.contributor.authorBolat, Ecem
dc.contributor.authorEker, Furkan
dc.contributor.authorKaplan, Merve
dc.contributor.authorDuman, Hatice
dc.contributor.authorArslan, Aysenur
dc.contributor.authorSaritas, Suemeyye
dc.contributor.authorSahutoglu, Arif Sercan
dc.date.accessioned2025-01-27T20:38:38Z
dc.date.available2025-01-27T20:38:38Z
dc.date.issued2022
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractSevere Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), a unique beta-coronavirus, has caused the most serious outbreak of the last century at the global level. SARS-CoV-2 infections were firstly reported in the city of Wuhan in China in 2019 and this new disease was named COVID-19 by World Health Organization (WHO). As this novel disease can easily be transmitted from one individual to another via respiratory droplets, many nations around the world have taken several precautions regarding the reduction in social activities and quarantine for the limitation of the COVID-19 transmission. SARS-CoV-2 is known to cause complications that may include pneumonia, acute respiratory distress syndrome (ARDS), multi-organ failure, septic shock, and death. To prevent and treat COVID-19, some significant studies have been conducted since the outbreak. One of the most noticeable therapeutic approaches is related to a multifunctional protein, lactoferrin. Lactoferrin (Lf) is an 80 kDa cationic glycoprotein that has a great range of benefits from improving the immunity to antiviral effects due to its unique characteristics such as the iron-binding ability. This review summarizes the characteristics of SARS-CoV-2 and the potential applications of Lf for the prevention, treatment, and recovery of COVID-19.
dc.description.sponsorshipTUBITAK [118z146]; Uluova Suet Ticaret A.S. (Uluova Milk Trading Co.)
dc.description.sponsorshipUluova Suet Ticaret A.S. (Uluova Milk Trading Co.) and TUBITAK #118z146 have funded this study. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.
dc.identifier.doi10.3389/fnut.2022.992733
dc.identifier.issn2296-861X
dc.identifier.pmid36419551
dc.identifier.scopus2-s2.0-85142235859
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.3389/fnut.2022.992733
dc.identifier.urihttps://hdl.handle.net/20.500.12428/23680
dc.identifier.volume9
dc.identifier.wosWOS:000890590900001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherFrontiers Media Sa
dc.relation.ispartofFrontiers in Nutrition
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20250125
dc.subjectlactoferrin
dc.subjectCOVID-19
dc.subjectSARS-CoV-2
dc.subjectinflammation
dc.subjectiron homeostasis
dc.subjectspike proteins
dc.subjectACE2 receptor
dc.titleLactoferrin for COVID-19 prevention, treatment, and recovery
dc.typeReview Article

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu